VEGFA and neoplasm: Another possibility for the antiangiogenic activity of TMPs from cells exposed to anti-VEGF-A antibody could be due to the uptake of B20 antibodies either by tumor cells or by their TMPs, as recently was suggested that platelets can uptake bevacizumab, the humanized antibody against VEGF-A [38], and therefore it is plausible that such antibodies will be present in MPs.